QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer

The study consists of four cohorts, each planning to enroll 30 subjects. Cohort 1(advanced SCLC) and Cohort 3 (advanced squamous NSCLC) will receive later‐line treatmentwith QL1706 5 mg/kg intravenously once every 3 weeks (Q3W) plus anlotinib 10 mg orallyonce daily (qd). Cohort 2 (advanced SCLC) and Cohort 4 (advanced squamous NSCLC) willreceive anlotinib 10 mg orally once daily alone. Treatment continues until diseaseprogression (and the investigator determines that the subject no longer derives clinicalbenefit) or other criteria for study treatment discontinuation are met, whichever occursfirst.